- Home
- BCDA vs OSRH Comparison
BCDA vs OSRH Comparison
Compare BCDA & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- OSRH
- Stock Information
- Founded
- BCDA N/A
- OSRH N/A
- Country
- BCDA United States
- OSRH United States
- Employees
- BCDA N/A
- OSRH N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- OSRH
- Sector
- BCDA Health Care
- OSRH
- Exchange
- BCDA Nasdaq
- OSRH Nasdaq
- Market Cap
- BCDA 11.3M
- OSRH 13.2M
- IPO Year
- BCDA N/A
- OSRH N/A
- Fundamental
- Price
- BCDA $1.35
- OSRH $0.60
- Analyst Decision
- BCDA Strong Buy
- OSRH
- Analyst Count
- BCDA 1
- OSRH 0
- Target Price
- BCDA $25.00
- OSRH N/A
- AVG Volume (30 Days)
- BCDA 1.6M
- OSRH 988.8K
- Earning Date
- BCDA 11-12-2025
- OSRH 11-24-2025
- Dividend Yield
- BCDA N/A
- OSRH N/A
- EPS Growth
- BCDA N/A
- OSRH N/A
- EPS
- BCDA N/A
- OSRH N/A
- Revenue
- BCDA N/A
- OSRH $104,735.00
- Revenue This Year
- BCDA N/A
- OSRH N/A
- Revenue Next Year
- BCDA N/A
- OSRH N/A
- P/E Ratio
- BCDA N/A
- OSRH N/A
- Revenue Growth
- BCDA N/A
- OSRH N/A
- 52 Week Low
- BCDA $1.00
- OSRH $0.45
- 52 Week High
- BCDA $3.20
- OSRH $13.40
- Technical
- Relative Strength Index (RSI)
- BCDA 38.89
- OSRH 45.43
- Support Level
- BCDA $1.27
- OSRH $0.53
- Resistance Level
- BCDA $1.42
- OSRH $0.76
- Average True Range (ATR)
- BCDA 0.11
- OSRH 0.05
- MACD
- BCDA 0.01
- OSRH 0.00
- Stochastic Oscillator
- BCDA 70.00
- OSRH 35.47
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.